Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045689 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
A Phase 3 study of Myelodysplastic Syndromes, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT06045689: Active Phase 3 study of Myelodysplastic Syndromes, sponsored by Bristol-Myers Squibb.
NCT06045689 is a Phase 3 study of Myelodysplastic Syndromes that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06045689, a Phase 3 study of Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Conditions Studied
Interventions
- DRUG Luspatercept
Study Locations (20)
Florida
- Local Institution - 0055 - St. Petersburg
- Local Institution - 0056 - Wellington
Texas
- Local Institution - 0043 - Amarillo
- Local Institution - 0022 - Huntsville
Praha, Hlavní Mesto
- Local Institution - 0023 - Prague
- Local Institution - 0004 - Prague
California
- Local Institution - 0051 - Los Alamitos
Connecticut
- Local Institution - 0033 - New Haven
Kansas
- Local Institution - 0020 - Kansas City
Kentucky
- Local Institution - 0025 - Paducah
Michigan
- Local Institution - 0011 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
What the registry record for NCT06045689 still lists
NCT06045689 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Luspatercept is the first listed.
NCT06045689 names 20 study sites across 17 states, led by Florida, Texas, Praha, Hlavní Mesto.
Frequently Asked Questions
What is clinical trial NCT06045689 about?
NCT06045689 is a clinical study titled "A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants". The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
What is the current status of trial NCT06045689?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2023-10-05. Estimated completion is 2027-12-30.
What conditions does trial NCT06045689 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06045689?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT06045689?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06045689 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06045689's enrollment target sits among peer trials
106 52nd of 173 higher than 122 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
RECRUITING · Phase 3
-
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
ACTIVE NOT RECRUITING · Phase 3
-
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI